We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current SOLTF market cap is 583.19M. The company's latest EPS is JPY -80.4165 and P/E is -0.08.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 9.76B | 8.92B | 17.72B | 16.2B | 13.71B |
| Operating Income | 203M | 572M | 4.03B | 1.17B | -9.46B |
| Net Income | 1.43B | 1.48B | 1.02B | 1.77B | -7.19B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 56.68B | 76.47B | 96.99B | 99.42B | 157.2B |
| Total Liabilities | 11.6B | 24.08B | 39.52B | 41.48B | 90.39B |
| Total Equity | 45.08B | 52.38B | 57.47B | 57.94B | 66.81B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 3.44B | 4.67B | 7.1B | 9.95B | -5.27B |
| Investing | -246M | -150M | 278M | 1.04B | -63.79B |
| Financing | -6.96B | 20.28B | 11.12B | -4.89B | 48.33B |
| Market Cap | 583.19M |
| Price to Earnings Ratio | -0.08 |
| Price to Sales Ratio | 0.04 |
| Price to Cash Ratio | 0.01 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 89.45M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -34.14% |
| 52 Week High | 13.43 |
| 52 Week Low | 6.1575 |
| Spread (Intraday) | 1.32 (20.21%) |
| Company Name | Nxera Pharma Company Ltd (PK) |
| Address |
2-1, koji-machi chiyoda, tokyo 102-0083 |
| Website | https://www.sosei.com |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
